Data WHO/UNICEF & CDC · 21 October 2026 How grades work · Changelog · Corrections

Open Source Medicine Foundation

Saint Vincent and the Grenadines

Coverage to 2025 · cases to 2025

Vaccination rates and reported vaccine-preventable disease in Saint Vincent and the Grenadines, with a data-quality grade on every series.

← All countries · Americas

99%
MCV1
2025 · WHO/UNICEF estimate
99%
DTP3
2025 · WHO/UNICEF estimate
99%
IPV complete
2025 · WHO/UNICEF estimate
99%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported

Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.

Vaccination coverage

Vaccination coverage by antigen, latest WHO/UNICEF estimate, country-reported figure, trend since 2000 and data-quality grade
VaccineLatest estimateCountry-reportedTrend since 2000Data quality
BCGTuberculosis vaccine at birth97%2025 · WHO/UNICEF estimate97.4%BCG coverage: 2000 to 2025, latest 97% in 2025, lowest 62%, highest 99%.B · good
DTP1First dose of diphtheria-tetanus-pertussis99%2025 · WHO/UNICEF estimate98.8%DTP1 coverage: 2000 to 2025, latest 99% in 2025, lowest 92%, highest 99%.B · good
DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme)99%2025 · WHO/UNICEF estimate98.8%DTP3 coverage: 2000 to 2025, latest 99% in 2025, lowest 92%, highest 99%.B · good
IPV1First dose of inactivated polio vaccine99%2025 · WHO/UNICEF estimate98.8%IPV1 coverage: 2015 to 2025, latest 99% in 2025, lowest 54%, highest 99%.B · good
IPV completeInactivated polio vaccine, complete primary series99%2025 · WHO/UNICEF estimate98.8%IPV complete coverage: 2021 to 2025, latest 99% in 2025, lowest 90%, highest 99%.C · weak
MCV1First dose of measles-containing vaccine99%2025 · WHO/UNICEF estimate98.9%MCV1 coverage: 2000 to 2025, latest 99% in 2025, lowest 90%, highest 99%.B · good
MCV2Second dose of measles-containing vaccine99%2025 · WHO/UNICEF estimate99.6%MCV2 coverage: 2001 to 2025, latest 99% in 2025, lowest 73%, highest 99%.C · weak
RCV1First dose of rubella-containing vaccine99%2025 · WHO/UNICEF estimate98.9%RCV1 coverage: 2000 to 2025, latest 99% in 2025, lowest 90%, highest 99%.B · good
HepB3Third dose of hepatitis B vaccine99%2025 · WHO/UNICEF estimate98.8%HepB3 coverage: 2003 to 2025, latest 99% in 2025, lowest 31%, highest 99%.B · good
HepB birthHepatitis B birth dose within 24 hours99%2025 · WHO/UNICEF estimate99.9%HepB birth coverage: 2017 to 2025, latest 99% in 2025, lowest 30%, highest 99%.B · good
Hib3Third dose of Haemophilus influenzae type b vaccine99%2025 · WHO/UNICEF estimate98.8%Hib3 coverage: 2003 to 2025, latest 99% in 2025, lowest 27%, highest 99%.B · good
PCV1Pneumococcal conjugate vaccine, first dose—% · Administrative (country-reported)—too few pointsno data
PCV completePneumococcal conjugate vaccine, final dose of the schedule—% · Administrative (country-reported)—too few pointsno data
RotaCRotavirus vaccine, complete series—% · Administrative (country-reported)—too few pointsno data
Yellow feverYellow fever vaccine (countries at risk)0.5%2013 · Administrative (country-reported)0.5%too few pointsD · poor
MenAMeningococcal A conjugate (meningitis belt)—% · Administrative (country-reported)—too few pointsno data
JEJapanese encephalitis vaccine (countries at risk)—% · Administrative (country-reported)—too few pointsno data
TCVTyphoid conjugate vaccine—% · Administrative (country-reported)—too few pointsno data
PABProtection at birth against neonatal tetanus (maternal tetanus doses)100%2017 · Administrative (country-reported)100%PAB coverage: 2010 to 2017, latest 100% in 2017, lowest 8.12%, highest 100%.D · poor
HPV dose 1, girlsHPV programme coverage, first dose, girls18%2025 · WHO/UNICEF estimate—HPV dose 1, girls coverage: 2017 to 2025, latest 18% in 2025, lowest 3%, highest 18%.D · poor
HPV complete, girlsHPV programme coverage, complete series, girls18%2025 · WHO/UNICEF estimate—HPV complete, girls coverage: 2018 to 2025, latest 18% in 2025, lowest 4%, highest 18%.D · poor
HPV dose 1, boysHPV programme coverage, first dose, boys—% · Administrative (country-reported)—too few pointsno data

Reported vaccine-preventable disease

Reported cases and incidence by disease, latest year, trend since 2000 and data-quality grade
DiseaseReported casesIncidence rateTrend since 2000Data quality
Measles all countries · vaccine evidence020250per 1,000,000 total populationMeasles reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Rubella all countries · vaccine evidence020250per 1,000,000 total populationRubella reported cases: 2001 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Congenital rubella syndrome all countries · vaccine evidence020250per 10,000 live birthsCongenital rubella syndrome reported cases: 2001 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Mumps all countries · vaccine evidence020250per 1,000,000 total populationMumps reported cases: 2001 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Pertussis (whooping cough) all countries · vaccine evidence020250per 1,000,000 total populationPertussis (whooping cough) reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Diphtheria all countries · vaccine evidence020250per 1,000,000 total populationDiphtheria reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Tetanus (total) all countries · vaccine evidence020250per 1,000,000 total populationTetanus (total) reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Neonatal tetanus all countries · vaccine evidence020250per 1,000 live birthsNeonatal tetanus reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Polio (paralytic) all countries · vaccine evidence020250per 1,000,000 <15 populationPolio (paralytic) reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Yellow fever all countries · vaccine evidence020250per 1,000,000 total populationYellow fever reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Japanese encephalitis all countries · vaccine evidence020190per 1,000,000 total populationJapanese encephalitis reported cases: 2006 to 2019, latest 0 in 2019, lowest 0, highest 0.D · poor
Invasive meningococcal disease all countries · vaccine evidence020250per 1,000,000 total populationInvasive meningococcal disease reported cases: 2020 to 2025, latest 0 in 2025, lowest 0, highest 0.D · poor
Typhoid all countries · vaccine evidence020250per 1,000,000 total populationTyphoid reported cases: 2018 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak

National schedule (latest WHO listing)

Show the schedule (28 rows)
National immunization schedule
VaccineDoseAgeTarget groupComment
BCGBCG (Baccille Calmette Guérin) vaccine1B-M12General/routineBirth up to 1 year
COVID19COVID-19 vaccine1AdultsAll adults
COVID19COVID-19 vaccine1General/routineAll children and adolescents
COVID19COVID-19 vaccine1Health workersHealth and care workers
COVID19COVID-19 vaccine1Pregnant womenPregnant women
COVID19COVID-19 vaccine1Risk group(s)Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups
DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine5Y4General/routine
DTWPDTwP (Whole cell) vaccine4M18General/routine
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine1M2General/routine0-11 months
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine2M4General/routine0-11 months
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine3M6General/routine0-11 months
HEPB_ADULTAdult Hepatitis B (HepB) vaccine11st contactRisk group(s)Adults with no doccumented evidence of HepB
HEPB_ADULTAdult Hepatitis B (HepB) vaccine2+M1Risk group(s)Adults with no doccumented evidence of HepB
HEPB_ADULTAdult Hepatitis B (HepB) vaccine3+M5Risk group(s)Adults with no doccumented evidence of HepB
HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine1BGeneral/routineBirth - 24 hours
HPV2HPV-2 (Human papillomavirus 2-valent) vaccine1Y11-Y12HPV for females onlyUp to 20 years; Female
IPVIPV (Inactivated polio vaccine)1M2General/routineand immunocompromised children
IPVIPV (Inactivated polio vaccine)1Risk group(s)Immunocompromised children
IPVIPV (Inactivated polio vaccine)2M4General/routineand immunocompromised children
MMRMMR (Measles, mumps and rubella) vaccine1M12General/routine
MMRMMR (Measles, mumps and rubella) vaccine2M18General/routine
MRMR (Measles and rubella) vaccine11st contactAdultsAdults (like seafarers going to study)
MRMR (Measles and rubella) vaccine11st contactRisk group(s)Adults (like seafarers going to study)
OPVOPV (Oral polio vaccine)3M6General/routine
OPVOPV (Oral polio vaccine)4M18General/routine
OPVOPV (Oral polio vaccine)5Y4General/routine
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine6Y10General/routine
YFYF (Yellow fever) vaccine11st contactTravellersTravellers travelling to countries endemic to Yellow Fever

Compare schedules across 31 countries on the schedule hub.

Data and sources

Coverage figures are WHO/UNICEF estimates unless a row says otherwise; reported cases are what national authorities sent to WHO and undercount true infections. Each series carries a data-quality grade that says why.

Cite this page. Saint Vincent and the Grenadines. Vaccine Data Navigator, Open Source Medicine Foundation. Built 21 October 2026 from WHO/UNICEF (WIISE) exports and CDC SchoolVaxView. https://vaccinedatanavigator.org/disease-risk/countries/vct.html

Report an error